Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Randomized in the parent study, PCYC-1115-CA~2. Informed consent for Study PCYC-1116-CA~3. Independent review committee (IRC)-confirmed disease progression (PD) in the parent study PCYC-1115-CA or closure of the parent study~Exclusion Criteria:~1. Disease progression involving the central nervous system (CNS) or transformation to another histology~2. Intervening chemotherapy, immunotherapy, or investigational agent specifically to treat CLL if administered before date of IRC confirmed progressive disease~3. In the 4 weeks before dosing: radiation therapy, major surgery, or receipt of an investigational drug~4. Requirement for treatment with a strong CYP3A inhibitor~5. Uncontrolled systemic infection or requirement for IV antibiotics~6. Noncompliance on the parent study(PCYC-1115-CA)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorambucil (Type: EXPERIMENTAL): Participants who received chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) Days 1 and 15 of 28-day cycle up to 12 cycles in Study 1115. In Study 1116, participants had the option to crossover to next-line ibrutinib 420 mg/day after disease progression (PD).
- Ibrutinib (Type: EXPERIMENTAL): Participants who received ibrutinib 420 mg daily in Study 1115 received ibrutinib orally once daily. Participants continuing in first-line ibrutinib therapy entered Study 1116 at the ibrutinib dose tolerated in Study 1115.

Based on this trial design, predict the completion outcome and termination type (if applicable).